Abstract:Key PointsMuscle wasting is a debilitating condition that develops with ageing and more rapidly with inactivity (bed rest) and in various systemic diseases (for example, cancer, renal failure, chronic obstructive pulmonary disease, sepsis, HIV and trauma). Fibre atrophy primarily results from an acceleration of protein degradation, often combined with reduced protein synthesis. Treatments that prevent this activation of proteolysis or increase protein synthesis offer considerable promise to combat this debilitating process.Various types of rapid muscle wasting develop through a common transcriptional programme involving the induction of a set of atrophy-related genes (atrogenes) by forkhead box protein O (FOXO) transcription factors and reduced signalling by the PI3K–AKT–mTOR pathway.The resulting muscle weakness is a consequence of the degradation of myofibrils, which is catalysed by ubiquitin ligases that target different components of the contractile apparatus for proteasomal degradation. By contrast, the loss of endurance results from the breakdown of mitochondria via autophagy.Myostatin, an autocrine inhibitor of normal muscle growth, and its circulating homologue activin A, also trigger muscle protein loss in various catabolic states via the activation of SMAD2 and SMAD3, which function together with FOXO transcription factors.Antibodies against myostatin or activin A, or agents that block their receptor — activin A receptor, type IIB (ActRIIB) — in muscle could be a promising approach to combat muscle loss caused by cancer-associated cachexia, renal failure and ageing. Indeed, these treatments helped to preserve muscle and prolong longevity in tumour-bearing mice, and several of these treatments are currently in clinical trials.Glucocorticoids and various circulating inflammatory mediators, such as tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6), have also been implicated in excessive muscle proteolysis in cachexia, but their roles in different catabolic states remain uncertain and controversial.Recent studies have increased our understanding of the biochemical mechanisms of atrophy and have identified many intracellular proteins that are crucial in muscle wasting (for example, SMADs, tripartate motif-containing protein 32 (TRIM32), nuclear factor-κB (NF-κB)) or that combat this process (for example, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), sirtuin1 (SIRT1) and JUNB). Their manipulation by small molecules offers many opportunities for the rational design of new treatments for this condition.

Metronidazole treatment of women with a positive fetal fibronectin test result.

Muscle wasting in cancer

Molecular Mechanisms of Cachexia: A Review

Molecular mechanisms of cancer cachexia‐induced muscle atrophy (Review)

Cancer cachexia: molecular mechanisms and treatment strategies

Understanding cachexia as a cancer metabolism syndrome

Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting

Cancer cachexia prevention via physical exercise: molecular mechanisms

Is Cancer Cachexia Attributed to Impairments in Basal or Postprandial Muscle Protein Metabolism?

Cancer Cachexia: Signaling and Transcriptional Regulation of Muscle Catabolic Genes

Novel molecular targets of muscle wasting in cancer patients

Molecular mechanisms of cancer cachexia. Role of exercise training

The Pathway to Cancer Cachexia: MicroRNA-Regulated Networks in Muscle Wasting Based on Integrative Meta-Analysis

Cancer-associated cachexia — understanding the tumour macroenvironment and microenvironment to improve management

Modulating Metabolism to Improve Cancer-Induced Muscle Wasting

Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training

Developing and assessing teamwork skills in a multi-disciplinary course

Muscle wasting in disease: molecular mechanisms and promising therapies

Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia

The Cancer Cachexia Syndrome: A Review of Metabolic and Clinical Manifestations

Targeting cancer cachexia: Molecular mechanisms and clinical study